Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute oral versus intravenous sodium loading in type 2 diabetes and diabetic kidney disease with GLP-1 agonist challenge
NL-OMON27521Recruiting
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of Glucagon-like peptide 1 and sodium chloride in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and chronic kidney disease (CKD) (3 arms), sponsored by None. Primary endpoints: Cumulative urinary sodium balance at 24 hours and Fractional natriuresis at 24 hours. Started Jan 2020; status: recruiting.
02
Drugs
Glucagon-like peptide 1sodium chloride
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosischronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON27521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27521.